Novel biomarkers that are currently in development for PrCa include the TMPRSS2-ERG fusion, PCA3 and AMACR, each of which have been described for use alone or use in combination to improve the diagnosis of PrCa [4]. This evidence concerns the gene PCA3 and pure red-cell aplasia.